Hearts and Minds Investments (HM1) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
5 Jun, 2026Executive summary
Reported total comprehensive income after tax of $3.0 million for the half-year ended 31 December 2025, down from $115.3 million in the prior corresponding period.
Declared an increased interim fully franked dividend of 9.5cps, payable in April 2026, with a stated intention to increase by 0.5cps every 6 months.
Total shareholder return for the six months to 31 December 2025 was 7.9%, driven by share price appreciation and dividend payments.
Investment portfolio performance was flat, with a 0.4% return after expenses and before taxes, compared to 23.6% in the previous half-year.
Over $90.5 million has been donated to Australian medical research since 2016, with $5.4 million paid in the half-year to December 2025.
Financial highlights
Net income for the period was $4.5 million, with total comprehensive income of $3.0 million.
Basic and diluted EPS was 1.96 cents, down from 40.15 cents in the prior period.
Total investment income was $13.6 million, significantly lower than $137.5 million in the prior half-year.
Share price increased 4.9% over the half-year, with a total shareholder return of 7.9% including dividends.
Since inception, annualised investment return is 10.8% per annum.
Outlook and guidance
Interim fully franked dividend of 9.5 cents per share declared, payable on 16 April 2026.
Board intends to continue increasing fully franked dividends by 0.5cps every 6 months, subject to no sustained market underperformance.
Dividend policy is supported by a franking balance and tax liabilities sufficient to support 83cps of fully franked dividends.
No other significant events or changes in outlook reported post period-end.
Latest events from Hearts and Minds Investments
- FY24 saw an 11.7% portfolio return, 20% shareholder return, and increased fully franked dividends.HM1
H2 20249 Jun 2026 - FY25 saw a 25.5% portfolio return, higher dividends, and strong support for medical research.HM1
H2 20259 Jun 2026 - Half-year profit hit $115.3M, with strong returns and a higher dividend declared.HM1
H1 20255 Jun 2026 - Strong returns, higher dividends, and active management drive performance and philanthropy.HM1
AGM 20243 Feb 2026 - Strong returns, rising dividends, and major medical research funding highlighted at AGM.HM1
AGM 202526 Nov 2025